​1. Market Overview and Growth Drivers​ The global ​Zolpidem market—driven by rising insomnia prevalence and demand for non-benzodiazepine sedatives—is projected to reach ​​$2.8 billion by 2033, growing at a ​CAGR of 4.8%​​ . Zolpidem tartrate, the active ingredient in Sanofi’s Ambien®, remains the gold standard for short-term insomnia treatment, with generics accounting for ​75% of global sales​ . Key growth drivers include: ​2. Key Buyer Categories and Procurement Patterns​ ​2.1 Pharmaceutical Companies​ Major buyers include: ​2.2 Consumer Healthcare Brands​ ​2.3 Veterinary and Specialty Buyers​ Table: Zolpidem Market Share by Application (2023) ​Segment​ ​Market Share​ ​Key Buyers​ ​Pharmaceuticals 55% Teva, Mylan, Aurobindo ​Consumer Care​ 30% Reckitt Benckiser, GSK ​Veterinary​ 10% Zoetis,…